Regen Report · Apr 2026
A long-form interview describing how iDEM automates adherent stem-cell workflows, the CDMO launch, and the first site at CGT Catapult’s Stevenage manufacturing center.
Company research
Public company, workplace, funding, and market signals
Overview
Mytos is a London-based biotechnology company building an automated CDMO and iDEM robotics platform to scale regenerative-medicine cell manufacturing by automating cell culture, process/analytical development, and regulatory support.
Primary product
iDEM-powered automated CDMO for regenerative medicine and cell therapy manufacturing
Founded
2016
Headquarters
London, England, United Kingdom
Team size
11-50
Work style
Hybrid
Industry
Biotechnology Research
Sub-industry
Cell manufacturing / regenerative medicine / automated CDMO
Offices